First, they add to concerns that have been raised regarding the use of anti-PrP antibodies as therapeutic tools for treatment of prion diseases (White et al., 2003) and Alzheimer’s disease (Klyubin et al., 2014), given the potential side-effects of these reagents on neuronal viability at nanomolar concentrations (Reimann et al., 2016; Solforosi et al., 2004; Sonati et al., 2013). Here, PRNP is linked to early-onset autosomal dominant Alzheimer disease.